• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Switzerland Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Switzerland Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373260
  • January 2013
  • Region: Switzerland
  • 86 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Profile
  • GlaxoSmithKline
  • Merck & Co
  • Merck Serono
  • Novartis
  • Pfizer
  • MORE

BMI View:

While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients' attitudes towards these drugs as this is the main growth deterrent.

Headline Expenditure Projections

- Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% decline in local currency terms and -8.3% in US dollar terms.

- Healthcare: CHF65.30bn (US$73.8bn) in 2011 to CHF67.56bn (US$71.87bn) in 2012; +3.5% growth in local currency terms and -2.6% in US dollar terms.

- Medical devices: CHF4.77bn (US$5.38bn) in 2011 to CHF4.76bn (US$5.06bn) in 2012; -0.3% growth in local currency terms and -5.9% in US dollar terms.

Risk/Reward Ratings: In BMI's Q113 risk/reward ratings (RRRs) for Western Europe, Switzerland has maintained its position as the top market in the Western Europe matrix, above the UK and France.

Switzerland's score for the quarter stands at 70.9, well above the regional average of 65.8. However, READ MORE >

FEATURED COMPANIES

  • Company Profile
  • GlaxoSmithKline
  • Merck & Co
  • Merck Serono
  • Novartis
  • Pfizer
  • MORE

BMI Industry View 7

Executive Summary 7

SWOT 9

Switzerland Pharmaceuticals And Healthcare Industry SWOT 9

Industry Forecast 11

Overall market Forecast 11

Key Growth Factors - Industry 13
Table: Table: Healthcare Expenditure Indicators 2009-2016 15
Table: Table: Healthcare Governmental Indicators 2009-2016 16
Table: Table: Healthcare Private Indicators 2009-2016 16

Economic Analysis 16
Table: Macro Indicators 21

Prescription Drug Market Forecast 22
Table: Table: Prescription Drug Sales Indicators 2009-2016 23

Patented Drug Market Forecast 24
Table: Table: Patented Drug Market Indicators 2009-2016 25

Generic Drug Market Forecast 25
Table: Table: Generic Drug Sales Indicators 2009-2016 28

OTC Medicine Market Forecast 28
Table: Table: OTC Medicine Sales Indicators 2009-2016 29

Pharmaceutical Trade Forecast 30
Table: Table: Exports and Imports Indicators 2009-2016 31

Medical Device Market Forecast 32
Table: Table: Medical Devices Sales Indicators 2009-2016 33

Other Healthcare Data Forecasts 33

Industry Risk Reward Ratings 36

Pharmaceutical Risk/Reward Ratings 36
Table: Western Europe Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113 36

Market Overview 39

Market Overview 39

Industry Trends And Developments 41

Industry Trends And Developments 41
Table: 2013: Health Insurance Premiums 42

Regulatory Development 50

Regulatory Regime 50

Competitive Landscape 58

Competitive Landscape 58

Company Profile 61

Novartis 61

Roche 65

Merck Serono 68

GlaxoSmithKline 71

Pfizer 74

Sanofi 76

Merck & Co 78

Methodology 80

Methodology 80

Risk/Reward Ratings Methodology 80

Ratings Overview 81
Table: Pharmaceutical Business Environment Indicators 81

Weighting 82
Table: Weighting Of Components 82

Sources 82

Glossary 84

Glossary 84

Demographic Forecast 86

Company Profile
Novartis
Roche
Merck Serono
GlaxoSmithKline
Pfizer
Sanofi
Merck & Co

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos